### SGLT2 Inhibitors and Kidney Stone Risk in Type 2 Diabetes Patients People with type 2 diabetes who are treated with a class of drugs known as sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) have a significantly lower risk of developing kidney stones. These drugs include Bexagliflozin (Brenzavvy), Canagliflozin (Invokana), Dapagliflozin (Farxiga), and Empagliflozin (Jardiance). A recent study published in JAMA Internal Medicine found that patients with type 2 diabetes taking SGLT2 inhibitors had a 31% lower risk of developing kidney stones compared to those taking other common diabetes medications. Specifically, the study showed a 26% lower risk when compared to another class of drugs known as dipeptidyl peptidase-4 (DPP4) inhibitors. The study highlighted that the reduced risk was consistent across different groups, regardless of sex, race, ethnicity, history of chronic kidney disease, or obesity. Interestingly, adults under the age of 70 experienced a greater reduction in risk compared to those over 70, although the reasons for this are not yet clear. Given the rising cases of kidney stones, especially among those with type 2 diabetes, this finding is significant. Kidney stones can cause severe pain and may lead to a decline in kidney function. Therefore, the individual risk profile for developing kidney stones could be an important consideration when deciding which glucose-lowering medication to prescribe for patients with type 2 diabetes.